… , dabigatran vs apixaban, and rivaroxaban vs apixaban were performed following … relative
effectiveness and safety of dabigatran vs VKA among the PS-trimmed and PS-matched patient …

… , Antwerp, Belgium; 6Faculty of Medicine and Life Sciences, Hasselt University, Hasselt,
Belgium; 7Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany; …

… composite DOACs and apixaban (number needed to treat, NNT 101 … in Germany: dabigatran,
rivaroxaban, apixaban and … to decisions in daily clinical practice, several limitations hold …

… Germany has steadily increased and since 2016 exceeded the number of previously preferred
vitamin K antagonists … observable, as dabigatran and apixaban user show a higher stroke …

… initiators; apixaban and warfarin patients were also more likely … of anticoagulants in routine
clinical practice. Other strengths … cohorts for comparative effectiveness assessment across the …

… safety or efficacy were observed between apixaban 2.5 mg BID and vitamin K antagonists in
patients with atrial fibrillation … in Germany, randomized comparison of a standardized NOAC …

… (double versus triple therapy and apixaban versus VKA), for … trials, we prioritized comparative
data of apixaban+SAPT and … versus triple therapy regimens were available (ie, for patient …

… of current Polish AF patients and cardiologist practices, which will provide … efficacy, and
safety of Apixaban in patients with non-valvular atrial fibrillation in unselected patients in Germany…

… there is no RCT comparing efficacy and safety of DOACs and … that ld-DOAC therapy,
as practiced in Germany today, might … efficacy, and safety of Apixaban in patients with non-Valvular …

… Germany)) are all authorized in Europe as valid alternatives for vitamin K antagonists (VKA)
in patients with non-valvular … from clinical practice on both the effectiveness and the safety of …